✦ LIBER ✦

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib

✍ Scribed by Smith, John C.; Brooks, Laura; Hoff, Paulo M.; McWalter, Gael; Dearden, Simon; Morgan, Shethah R.; Wilson, David; Robertson, Jane D.; Jürgensmeier, Juliane M.

Book ID: 123489353
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 590 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.02.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

KRAS mutational status assessment in pat

KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

✍ M. HEBBAR; P. FOURNIER; O. ROMANO 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

KRAS and BRAF Mutations in Advanced Colo

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

✍ Richman, S. D.; Seymour, M. T.; Chambers, P.; Elliott, F.; Daly, C. L.; Meade, A 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 164 KB

Chromosomal instability and p53 inactiva

Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation

✍ Leung, Suet Yi; Yuen, Siu Tsan; Chan, Tsun Leung; Chan, Annie SY; Ho, Judy WC; K 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 245 KB

3014 (Presidential session, Tue 25 Sep 1

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

✍ D. Freeman; T. Juan; N.J. Meropol; J.R. Hecht; J. Berlin; E. van Cutsem; M. Rein 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB